Study Title:
The Role of Our Gut Bacteria in Alzheimer’s Disease
Study Description:There are over 1000 types of bacteria that live in our gut and help us to process foods and help in nutrient and vitamin uptake. Recently, it was discovered that there are disturbances in the gut bacteria of people who have Alzheimer’s disease. Laboratory tests can determine the number and type of gut bacteria from a stool sample.
This information will help to compare the gut bacteria in people living with memory problems such as Alzheimer’s disease to those who do not have memory problems. This research may help develop therapies to improve unhealthy gut bacteria which may be able to improve the symptoms of Alzheimer’s disease and/or slow its progression.
Eligibility Criteria:
- Individuals age 50+ who:
- Are not experiencing any memory problems; OR
- Have Alzheimer’s disease
- Are prepared to provide 2 stool samples, 3-6 months apart, and fill out questionnaires
Recruitment Close Date:
Principal Investigator:
Dr. Andrew Frank
Contact:
Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.org
REB#:
M16-19-039. This study has been approved by the Bruyère Research Ethics Board.
Study Title:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participant with Early Alzheimer’s Disease
Study Description:This study’s purpose is to determine if the investigational drug AL002 is effective and safe in treating individuals who have mild Alzheimer’s disease when compared to placebo (non-active).
The investigational drug (AL002) aims to stimulate the body’s immune response to remove protein waste that is thought to contribute to Alzheimer’s disease. Participants in the study will receive the investigational product (or placebo) intravenously once every 4 weeks.
Eligibility Criteria:
- Aged between the years 50 to 85 years of age
- Have a diagnosis of Mild Cognitive Impairment, Mild Dementia or Mild Alzheimer’s
- Has someone who can be their study partner
- Note: This list is not exhaustive. Please contact the Clinical Trials Research Unit to find out more.
Recruitment Close Date:
31-Dec-2022
Principal Investigator:
Dr. Andrew Frank
Contact:
Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.org
REB#:
M16-21-015. This study has been approved by the Bruyère Research Ethics Board.
Study Title:A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer’s Disease
Study Description:Alzheimer’s disease is the most common cause of dementia and it continues to grow worldwide as the population ages. Approved drug treatments have modest effects so there is a great need to develop long-term symptomatic improvement, with few side effects.
Montelukast buccal film is a thin edible film that is placed on the inside of the cheek, delivering medication as the film dissolves. It is currently marketed as Singulair®, an anti-inflammatory, for the treatment of asthma but research has suggested that Montelukast may play some role in lowering the chance of developing dementia later in life and might be able to improve learning, memory and overall cognitive functions. This study aims to formally test Montekulast as a potential treatment for Alzheimer’s disease.
Eligibility Criteria:- Aged 50 years or older
- Has a diagnosis of mild to moderate Alzheimer’s disease
- Have a study partner accompany them throughout the study
- Note: The eligibility criteria list is not exhaustive. Please contact the study team to find out the full eligibility criteria.
Recruitment Close Date:
September 30, 2022
Principal Investigator:Dr. Andrew Frank
Contact: Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.orgREB#:M16-19-015. This study has been approved by the Bruyère Research Ethics Board.
Study Title:Assessing the safety, tolerability, and efficacy of the oral research drug in Early Symptomatic Alzheimer’s Disease
Study Description:In Alzheimer’s disease, protein function is no longer under control causing proteins to build up. One of these proteins is called Tau protein. When Tau protein builds up, it is thought to be linked with the decline of cognition, motor, and functional abilities in Alzheimer’s disease.
This research study is investigating if an oral research drug, which aims to reduce tau protein build up, will help slow the progression of decline in Alzheimer’s disease.
Eligibility Criteria:- Aged 60 to 85 years
- Gradual and progressive change in memory function reported by the participant or informant for ≥ 6 months
- Have a study partner that will accompany participant to select visits and participate in select visits
- Note: The eligibility criteria list is not exhaustive. Please contact team to find out the full eligibility criteria from the study team.
Recruitment Close Date:November 2022
Principal Investigator:Dr. Andrew Frank
Contact:Clinical Trials Research Unit: 613-562-6328 or
ctu@bruyere.orgREB#: M16-21-044. This study has been approved by the Bruyère Research Ethics Board.